The US FDA has authorized a new drug to treat Alzheimer's disease, marking the first approval of a drug for the disease in nearly 20 years. The drug, called Aduhelm, has sparked controversy due to its high cost and mixed clinical trial results. Some experts believe the approval sets a dangerous precedent for the FDA's drug approval process.

Aduhelm's approval highlights the complex balance between innovation and rigorous standards. While offering hope, it underscores the need for transparent evaluation and cost considerations in advancing Alzheimer's treatment.